292 filings
Page 7 of 15
8-K
c4qb8v bj
10 Aug 20
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
8:23am
8-K
xsdmy5xm nyv8w9jm7a
5 Aug 20
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
7:05am
8-K
n9nlr
13 Jul 20
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major
7:06am
8-K
l2ivqq
26 Jun 20
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
7:05am
8-K
upwc52
8 Jun 20
Departure of Directors or Certain Officers
12:00am
DEFA14A
ub7 d53pr
26 May 20
Additional proxy soliciting materials
7:04am
S-8
bci 5arh7m
11 May 20
Registration of securities for employees
5:12pm
8-K
x14ddw0
8 May 20
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
4:49pm
8-K
1d1awaf4uh766k64 vrs
27 Apr 20
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation
8:00am
DEFA14A
edo4myk0 wqq
21 Apr 20
Additional proxy soliciting materials
5:08pm
8-K
ircbwb of
21 Apr 20
Departure of Directors or Certain Officers
5:04pm
8-K
jl616x
6 Apr 20
Other Events
8:18am
8-K
4b7dv6u4cy39kuq
30 Mar 20
Other Events
9:47am
8-K
lmrmt
20 Mar 20
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
7:05am
8-K
4f8wa8ea5dqx4
12 Mar 20
Other Events
4:49pm
8-K
y5gxcirk
12 Mar 20
Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
7:07am